NCT04179019View on ClinicalTrials.gov

Calcium Channel Blockade in Primary Aldosteronism

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Primary AldosteronismPrimary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Interventions
DRUG

Amlodipine

Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks

Trial Locations (1)

02115

Anand Vaidya, Boston

All Listed Sponsors
collaborator

University of Michigan

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT04179019 - Calcium Channel Blockade in Primary Aldosteronism | Biotech Hunter | Biotech Hunter